OverviewSuggest Edit

Galera Therapeutics is a clinical-stage biotech company focused on the development of drugs targeting the oxygen metabolic pathways. The company's lead compounds are small molecule dismutase mimetics which closely mimic the activity of the human superoxide dismutase enzymes.

TypePublic
Founded2009
HQMalvern, US
Websitegaleratx.com

Latest Updates

Employees (est.) (Sept 2019)26
Share Price (Nov 2020)$11 (+2%)
Cybersecurity ratingAMore

Key People/Management at Galera Therapeutics

J. Mel Sorensen

J. Mel Sorensen

President and Chief Executive Officer
Robert A. Beardsley

Robert A. Beardsley

Chief Operating Officer
Dennis P. Riley

Dennis P. Riley

Chief Scientific Officer
Jon T. Holmlund

Jon T. Holmlund

Chief Medical Officer
Arthur Fratamico

Arthur Fratamico

Chief Business Officer
Chris Degnan

Chris Degnan

Chief Financial Officer
Show more

Galera Therapeutics Office Locations

Galera Therapeutics has an office in Malvern
Malvern, US (HQ)
2 W Liberty Blvd #110
Show all (1)

Galera Therapeutics Financials and Metrics

Galera Therapeutics Revenue

USD

Net income (Q2, 2020)

(18.7m)

EBIT (Q2, 2020)

(17.7m)

Market capitalization (20-Nov-2020)

270.5m

Closing stock price (20-Nov-2020)

11.0

Cash (30-Jun-2020)

15.9m

EV

255.3m
Galera Therapeutics's current market capitalization is $270.5 m.
Annual
USDFY, 2017FY, 2018FY, 2019

General and administrative expense

3.5m5.6m8.4m

R&D expense

20.6m18.7m42.3m

Operating expense total

24.1m24.3m50.7m

EBIT

(24.1m)(24.3m)(50.7m)
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020

General and administrative expense

1.8m3.6m3.9m

R&D expense

11.0m14.3m13.8m

Operating expense total

12.9m17.8m17.7m

EBIT

(12.9m)(17.8m)(17.7m)
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

6.2m14.8m18.4m

Prepaid Expenses

479.0k1.5m5.3m

Current Assets

15.2m83.9m117.6m

PP&E

325.0k568.0k934.0k
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

16.2m15.7m21.6m15.9m

Prepaid Expenses

2.7m4.2m4.5m4.0m

Current Assets

84.0m72.1m125.0m108.4m

PP&E

948.0k970.0k892.0k1.2m
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(23.5m)(23.7m)(51.9m)

Depreciation and Amortization

84.0k127.0k267.0k

Accounts Payable

(652.0k)1.6m77.0k

Cash From Operating Activities

(23.4m)(22.2m)(46.7m)
Quarterly
USDQ2, 2018Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(9.9m)(21.9m)(35.3m)(18.4m)(37.1m)

Depreciation and Amortization

56.0k113.0k188.0k80.0k175.0k

Accounts Payable

(206.0k)1.4m1.1m2.7m2.8m

Cash From Operating Activities

(10.5m)(18.5m)(31.4m)(12.4m)(27.8m)
USDFY, 2017

Financial Leverage

-0.2 x
Show all financial metrics

Galera Therapeutics Operating Metrics

Oct, 2019

Patents (Foreign)

69

Patents (US)

15

Phase I Trials Products

1

Phase III Trials Products

1
Show all operating metrics

Galera Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Galera Labs
Galera Therapeutics Australia Pty Ltd

Galera Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Galera Therapeutics Online and Social Media Presence

Embed Graph

Galera Therapeutics News and Updates

Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

MALVERN, Pa., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced …

Galera Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates

Presented Promising Interim Data from Placebo-controlled Pilot Dismutase Mimetic SBRT Combination Trial for Pancreatic Cancer

Galera Therapeutics Announces Positive Interim Data from First Cohort of Patients in Pilot Phase 1/2 Clinical Trial of GC4419 in Pancreatic Cancer

Interim data on first 19 patients released in ASTRO Annual Meeting late-breaker presentation abstract showed improvement in overall survival and multiple anti-cancer efficacy measures

Galera Therapeutics to Host Virtual KOL Event on the Treatment of Locally Advanced Pancreatic Cancer

MALVERN, Pa., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced…

Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 for COVID-19

Trial to enroll up to 50 hospitalized adults critically ill with COVID-19

Galera Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

MALVERN, Pa., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced…
Show more

Galera Therapeutics Blogs

Galera Therapeutics Appoints Christopher Degnan as Chief Financial Officer

MALVERN, Penn. — October 10, 2019 — Galera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced Christopher Degnan has been n…

Galera Therapeutics Announces Two-Year Tumor Outcomes Data for GC4419

MALVERN, Penn. — October 8, 2019 — Galera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced final data from its two-year t…

Galera Therapeutics Announces Presentation of Data from Phase 2b Clinical Trial of Avasopasem Manganese at 2019 NCCN Annual Conference

MALVERN, Penn. — March 21, 2019 — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, today announced data from its Phase 2b clinical trial of lead product candi…

Data from Galera Therapeutics’ Phase 2b Clinical Trial of Avasopasem Manganese (GC4419) Presented at ASTRO Annual Meeting

MALVERN, Penn. — October 23, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, announced data from its Phase 2b clinical trial evaluating avasopasem man…

Galera Therapeutics Announces Dosing of First Patient in Pivotal Phase 3 ‘ROMAN’ Clinical Trial of Avasopasem Manganese (GC4419)

MALVERN, Penn. — October 15, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, today announced the first patient has been dosed in a Phase 3 clinical tr…

Galera Therapeutics Raises $150 Million for GC4419 Phase 3 Trial and Pre-Commercialization Activities in Lead Indication

MALVERN, Penn. — September 19, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, today announced it has secured $150 million in a joint, oversubscribed …
Show more

Galera Therapeutics Frequently Asked Questions

  • When was Galera Therapeutics founded?

    Galera Therapeutics was founded in 2009.

  • Who are Galera Therapeutics key executives?

    Galera Therapeutics's key executives are J. Mel Sorensen, Robert A. Beardsley and Dennis P. Riley.

  • How many employees does Galera Therapeutics have?

    Galera Therapeutics has 26 employees.

  • Who are Galera Therapeutics competitors?

    Competitors of Galera Therapeutics include VivaBioCell, Abcam and Xcell Biosciences.

  • Where is Galera Therapeutics headquarters?

    Galera Therapeutics headquarters is located at 2 W Liberty Blvd #110, Malvern.

  • Where are Galera Therapeutics offices?

    Galera Therapeutics has an office in Malvern.

  • How many offices does Galera Therapeutics have?

    Galera Therapeutics has 1 office.